Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Design principles to assemble drug combinations for effective tuberculosis therapy using interpretable pairwise drug response measurements
Jonah Larkins‐Ford, Yonatan N. Degefu, Nhi Van, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 9, pp. 100737-100737
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease
Véronique Dartois, Thomas Dick
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 5, pp. 381-403
Open Access | Times Cited: 27
DeepDrug as an expert guided and AI driven drug repurposing methodology for selecting the lead combination of drugs for Alzheimer’s disease
Victor O. K. Li, Yang Han, Tushar Kaistha, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum
Jansy P. Sarathy, Min Xie, R. Mark Jones, et al.
mBio (2023) Vol. 14, Iss. 2
Open Access | Times Cited: 19
Miltefosine and Nifuratel Combination: A Promising Therapy for the Treatment of Leishmania donovani Visceral Leishmaniasis
Estela Melcón-Fernández, Giulio Galli, Carlos García‐Estrada, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1635-1635
Open Access | Times Cited: 16
Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs
Kara Schmidlin, Sam Apodaca, Daphne Newell, et al.
eLife (2024) Vol. 13
Open Access | Times Cited: 4
Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs
Kara Schmidlin, Sam Apodaca, Daphne Newell, et al.
eLife (2024) Vol. 13
Open Access | Times Cited: 4
Chemical genetic interactions elucidate pathways controlling tuberculosis antibiotic efficacy during infection
Peter O. Oluoch, Eun‐Ik Koh, Megan K. Proulx, et al.
Proceedings of the National Academy of Sciences (2025) Vol. 122, Iss. 9
Open Access
Predicting fitness in Mycobacterium tuberculosis with transcriptional regulatory network-informed interpretable machine learning
Ethan Bustad, Edson Petry, Oliver Gu, et al.
Frontiers in Tuberculosis (2025) Vol. 3
Open Access
Advances in the design of combination therapies for the treatment of tuberculosis
Jonah Larkins‐Ford, Bree B. Aldridge
Expert Opinion on Drug Discovery (2022) Vol. 18, Iss. 1, pp. 83-97
Open Access | Times Cited: 21
Novel Synergies and Isolate Specificities in the Drug Interaction Landscape of Mycobacterium abscessus
Nhi Van, Yonatan N. Degefu, Pathricia A. Leus, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 67, Iss. 7
Open Access | Times Cited: 11
Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis
Michael A. Lyons, Andrés Obregón‐Henao, M. E. Ramey, et al.
Antimicrobial Agents and Chemotherapy (2024) Vol. 68, Iss. 5
Open Access | Times Cited: 3
Tools to develop antibiotic combinations that target drug tolerance in Mycobacterium tuberculosis
Talia Greenstein, Bree B. Aldridge
Frontiers in Cellular and Infection Microbiology (2023) Vol. 12
Open Access | Times Cited: 8
Advancing tuberculosis management: the role of predictive, preventive, and personalized medicine
Matúš Dohál, Igor Porvazník, Ivan Solovič, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 7
Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs across hundreds of fluconazole-resistant yeast strains
Kara Schmidlin, Sam Apodaca, Daphne Newell, et al.
(2024)
Open Access | Times Cited: 2
Chemical genetic interactions elucidate pathways controlling tuberculosis antibiotic efficacy during infection
Peter O. Oluoch, Eun‐Ik Koh, Megan K. Proulx, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access | Times Cited: 2
Design, Synthesis, and Activity Evaluation of Novel Dual-Target Inhibitors with Antifungal and Immunoregulatory Properties
Bin Sun, Wenxia Liu, Qingpeng Wang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 18, pp. 13007-13027
Closed Access | Times Cited: 6
The Combination of Membrane Disruption and FtsZ Targeting by a Chemotherapeutic Hydrogel Synergistically Combats Pathogens Infections
Xianyuan Wei, Jintong Guo, Xiaorui Geng, et al.
Advanced Healthcare Materials (2024) Vol. 13, Iss. 19
Open Access | Times Cited: 1
Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis
Allison Bauman, Jansy P. Sarathy, Firat Kaya, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
DeepDrug: An Expert-led Domain-specific AI-Driven Drug-Repurposing Mechanism for Selecting the Lead Combination of Drugs for Alzheimer’s Disease
Victor O. K. Li, Yang Han, Tushar Kaistha, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Antibiotic lethality dictates mycobacterial infection outcomes
Alexander Jovanovic, Frederick K. Bright, Ahmad Sadeghi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Catalase activity deficiency sensitizes multidrug-resistant Mycobacterium tuberculosis to the ATP synthase inhibitor bedaquiline
Boatema Ofori-Anyinam, Meagan Hamblin, Miranda L Coldren, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Characterizing the immune response to Mycobacterium tuberculosis: a comprehensive narrative review and implications in disease relapse
F Rahman
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Spatiotemporal perspectives on tuberculosis chemotherapy
Junhao Zhu, Yue J. Liu, Sarah M. Fortune
Current Opinion in Microbiology (2023) Vol. 72, pp. 102266-102266
Open Access | Times Cited: 4
Digital Research Environment(DRE)-enabled Artificial Intelligence (AI) to facilitate early stage drug development
Jeffrey S. Barrett, Solmaz Eradat Oskoui, Scott Russell, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 4
Inhibiting respiration as a novel antibiotic strategy
Bei Shi Lee, Samsher Singh, Kévin Pethe
Current Opinion in Microbiology (2023) Vol. 74, pp. 102327-102327
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top